Izun reports Phase II data for IZN-6N4 in oral mucositis

In October, Izun Pharmaceuticals Corp. (New York, N.Y.) reported data from a Phase II trial in 110 patients with head and neck cancer showing that oral IZN-6N4 led to less mouth and throat pain and soreness vs. placebo. IZN-6N4 also led to less weight loss vs. placebo throughout the course of radiotherapy.

The double-blind, U.S. and Israeli trial is evaluating the proportion of patients with WHO score 3-4 oral mucositis as its primary endpoint. The secondary endpoint is the incidence of grade 2-4 oral mucositis as measured by the WHO scale...